Conferencia de resultados del T2 de 2026 de Belite Bio (BLTE): revisión de Tinlarebant por la FDA y $780 millones en efectivo

Conclusiones clave

• La FDA aceptó la Solicitud de Nuevo Fármaco (NDA) de Belite Bio para Tinlarebant en la enfermedad de Stargardt bajo revisión prioritaria, fijando la fecha PDUFA para el 12 de febrero de 2027.
• Los datos de la Fase III del estudio DRAGON mostraron que la autofluorescencia cuantitativa (qAF) disminuyó aproximadamente un 2% con respecto al valor inicial a los 25 meses en los pacientes tratados con Tinlarebant, frente a un aumento de aproximadamente el 20% en el grupo de placebo.
• Los gastos de I+D en el Q2 de 2026 aumentaron a 18,2 millones de dólares desde los 11,0 millones de dólares del año anterior, debido principalmente al pago de regalías vinculado a la finalización del estudio de Fase III.
• La pérdida neta GAAP se amplió a 28,4 millones de dólares frente a los 16,3 millones de dólares en el Q2 de 2025. La pérdida neta no GAAP aumentó a 21,6 millones de dólares desde los 8,7 millones de dólares.
• Belite Bio cerró el trimestre con 780 millones de dólares en efectivo, equivalentes de efectivo y letras del Tesoro de EE. UU. La gerencia afirmó que esto proporciona financiación para comercializar Tinlarebant tras su potencial aprobación y hacer avanzar la cartera de proyectos.
• La empresa está priorizando la revisión en Estados Unidos. La gerencia prevé una solicitud en Europa tras la potencial aprobación de la FDA, mientras que el proceso ante la PMDA en Japón avanza en paralelo.

Datos financieros clave

Rendimiento comercial y operativo

Tinlarebant continuó siendo el foco principal de la llamada de resultados del Q2 de 2026 de Belite Bio. La FDA aceptó la NDA para la enfermedad de Stargardt con revisión prioritaria y asignó la fecha PDUFA del 12 de febrero de 2027.

Belite Bio presentó los resultados de la Fase III del estudio DRAGON en cuatro congresos médicos en cuatro países. En la Reunión Anual de la Sociedad Estadounidense de Especialistas en Retina (American Society of Retina Specialists), la empresa informó que la qAF se mantuvo en un leve descenso en los pacientes tratados con Tinlarebant, cayendo aproximadamente un 2% desde el valor inicial al mes 25. Los pacientes con placebo registraron un aumento de aproximadamente el 20% durante el mismo periodo.

La gerencia describió la qAF como un marcador de acumulación tóxica de bisretinoides, un factor determinante de la degeneración retiniana en la enfermedad de Stargardt. La empresa afirmó que el resultado es coherente con el mecanismo de acción de Tinlarebant y su potencial para frenar el crecimiento de las lesiones.

El cumplimiento de la dosificación en el programa de Stargardt se mantuvo por encima del 90% después de 24 meses, según la gerencia.

DRAGON II sigue siendo un estudio centrado principalmente en Japón para la PMDA. Actualmente, la gerencia no prevé que contribuya a la revisión de la NDA en Estados Unidos. Belite Bio también está iniciando un estudio pediátrico en Londres para fundamentar los procesos regulatorios destinados a pacientes menores de 12 años.

Orientación de la gerencia

La gerencia afirmó que obtener la aprobación en Estados Unidos es su máxima prioridad durante los próximos seis meses. La empresa prevé presentar la solicitud en Europa tras una eventual aprobación de la FDA, de modo que su estrategia regulatoria y sus comunicaciones puedan alinearse entre las distintas jurisdicciones.

El proceso regulatorio en Japón avanza en paralelo con la revisión en Estados Unidos. Basándose en la designación Sakigake, la gerencia señaló que la aprobación japonesa podría producirse unos tres meses después de una eventual aprobación de la FDA.

Belite Bio prevé ahora el análisis intermedio de su estudio sobre la atrofia geográfica para el primer trimestre de 2027, probablemente después de febrero, ya que se espera que diciembre de 2026 y enero de 2027 sean el periodo de mayor actividad de interacción con la FDA.

Si se aprueba Tinlarebant, la gerencia prevé que la empresa reciba un vale de revisión prioritaria basado en su designación para enfermedades pediátricas raras. Belite Bio aún no ha decidido si venderá o utilizará dicho vale.

Riesgos y puntos a seguir

• La aprobación de la FDA sigue sujeta al proceso de revisión en curso antes de la fecha PDUFA del 12 de febrero de 2027.
• La gerencia indicó que actualmente no hay programada ninguna reunión del comité asesor, pero la FDA aún podría solicitar una más adelante durante la revisión.
• Aún no se han producido las conversaciones sobre la ficha técnica. La gerencia prevé una indicación más amplia según los datos disponibles, pero declinó hacer comentarios sobre la ficha técnica final potencial mientras la NDA se encuentra en revisión.
• El cronograma para la solicitud en Europa, la aprobación en Japón y el análisis intermedio de la atrofia geográfica sigue estando condicionado al proceso de la FDA y a una eventual aprobación en Estados Unidos.

Puntos destacados de las preguntas y respuestas de los analistas

Los analistas se centraron en el papel del DRAGON II, el desarrollo pediátrico, el orden de las fases regulatorias, la fabricación, el alcance potencial de la ficha técnica y la planificación del efectivo. La gerencia reiteró que DRAGON II está destinado principalmente a Japón y no se espera que respalde el proceso de la NDA en Estados Unidos.

En cuanto al alcance de la ficha técnica, la empresa afirmó que la FDA aún no ha debatido sobre la misma. El director médico, Hendrik Scholl, señaló que las tasas de progresión de las lesiones son ampliamente similares entre los grupos de edad y que la disfunción subyacente de ABCA4 es la misma, pero enfatizó que la empresa no hará predicciones sobre la ficha técnica final durante la revisión.

Belite Bio confirmó que trabaja con organizaciones de fabricación y desarrollo por contrato tanto en Estados Unidos como fuera de este país. La empresa no ofreció más detalles sobre las instalaciones durante la llamada.

La gerencia también afirmó que planea celebrar un Día Comercial virtual en septiembre, en el que pretende presentar hallazgos sobre el número de pacientes a partir de su estudio de mercado en Estados Unidos.

Transcripción completa de la llamada de resultados

Transcripción completa de la conferencia de resultados

Comentarios de la dirección

Operator

Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio Second Quarter 2026 Earnings Call. [Operator Instructions].

I will now hand the conference over to Julie Fallon. Please go ahead.

Julie Fallon

Thank you for joining us. On the call today are Dr. Tom Lin, Chairman and CEO of Belite Bio; Dr. Hendrik Scholl, Chief Medical Officer; Dr. Nathan Mata, Chief Scientific Officer; and Hao-Yuan Chuang, Chief Financial Officer.

Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today, we will be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today.

And now I'll turn the call over to Dr. Lin. Dr. Lin?

Yu-Hsin Lin

Thank you, Julie. Good afternoon, everyone. Thank you for joining our second quarter 2026 Financial Results and Corporate Update Call. The first half of this year has been both exciting and deeply productive for Belite Bio. As we rapidly approach a potential regulatory approval of Tinlarebant for Stargardt disease in the U.S.

We are very pleased to announce that the FDA has accepted our new drug application for Tinlarebant with priority review and establishing a PDUFA date of February 12, 2027. We believe this reflects the strength, consistency and depth of clinical data generated across our development program.

In parallel with our pre-commercial preparations, we remain highly engaged with the medical and patient communities. The enthusiasm we are seeing underscores the profound need for a new treatment paradigm in Stargardt disease. This quarter, we presented our Phase III DRAGON study results at 4 medical conferences across 4 countries, including the recent American Society of Retina Specialists, ASRS, Annual Meeting. At ASRS, we presented new secondary endpoint data, demonstrating subjects treated with Tinlarebant showed a hold to slightly decrease qAF values decreased by approximately 2% at month 25 compared to baseline. In contrast, subjects in the placebo group exhibited an approximately 20% increase in qAF values over the same period.

Quantitative autofluorescence or qAF is a marker of toxic bisretinoid accumulation, a key driver of retinal degeneration in Stargardt disease. The prevention or reduction of qAF strongly aligns with Tinlarebant mechanism of action, reinforcing its potential to hold or slow lesion growth. Looking ahead, we remain confident in our data, our science and the transformative potential of Tinlarebant for patients living with Stargardt disease. We look forward to providing further updates as they become available.

I'll now turn the presentation over to Hao-Yuan to discuss the financials. Hao?

Hao-Yuan Chuang

Thank you, Tom. We have had a strong first half of the year and continue to execute well against our plan. Let me recap our financial statements. For the second quarter of 2026, Our R&D expenses were $18.2 million compared to $11 million for the same period in 2025. The increase was primarily due to a royalty payment for additional milestone achieved under the license agreement. On a non-GAAP basis, excluding share-based compensation expenses, R&D expenses for second quarter were $17.2 million compared to $8.6 million in the second quarter of 2025. SG&A expenses in Q2 was $16.7 million compared to $6.5 million for the same period in 2025. The increase was primarily due to increase in professional service fee, wages and salary resulting from our team expansions.

On a non-GAAP basis, SG&A expenses for the second quarter were $10.9 million compared to $1.3 million in 2025 second quarter. The GAAP net loss in the second quarter was $28.4 million compared to $16.3 million in the same quarter in 2025. On a non-GAAP basis, we reported a net loss of $21.6 million for the second quarter compared to $8.7 million in 2025 same quarter. We ended the quarter with $780 million in cash, cash equivalents and U.S. treasury bills. Overall, our balance sheet remains very strong, and we are extremely well funded into the future with a cash runway to commercialize Tinlarebant following a potential regulatory approval and to continue to advance our pipelines.

With that, I'll now turn the call back to the operator for Q&A. Operator?

Operator

[Operator Instructions]. First question comes from the line of Judah Frommer with Morgan Stanley.

Preguntas y respuestas

Judah Frommer

Congrats on the progress. A couple from us. I guess with the NDA accepted now, what are your thoughts on the role that DRAGON II can play for the U.S. filing and/or regulatory process, any incremental interaction with FDA that would shed light on what that trial could be potentially utilized for in the U.S? And then, latest thinking on going lower in age going into peds for Tinlarebant , do you have trial plans to move the label below 12 years old in the near term?

Yu-Hsin Lin

Thanks. Good questions. For the DRAGON 2, I think at this stage, it's still pretty much a Japan study for the PMDA. Right now, we don't think -- we don't believe that the DRAGON II will contribute to the NDA process. As for the pediatric study, we do have plans, and I'll let Hendrik shed more light on the details of that study.

Hendrik Scholl

Yes, happy to. Thank you, Tom. So we are initiating a PIP study, a pediatric study in London, where we will investigate Tinlarebant in patients of BH3311 and this will be the basis to inform regulatory processes for patients that are younger than 12 years old.

Operator

And your next question Marc Goodman with Leerink.

Marc Goodman

Could you tell us how much the royalty payment was, the one-timer that's within R&D? Second question, just tell us what you're thinking with respect to European filing? And then third, have you done any claims database analysis to figure out like exactly the number of patients that are in the United States that have actually under the claims database?

Yu-Hsin Lin

Hao, do you want to take this, given that it's the royalty payment?

Hao-Yuan Chuang

Yes. Well, the first one is related to the completion of the Phase III study. And I can also take the third question. We will -- as we said on the press release, we do plan to host a Commercial Day event, it's going to be virtual in September, and we'll disclose about the numbers that we have surveyed about the question you just asked.

Marc Goodman

How much was the royalty payment?

Hao-Yuan Chuang

No, we cannot disclose that, Columbia asked us to keep that as a confidential, but yes, it's related to the Phase III completion.

Marc Goodman

Okay. And then just thoughts on European filing?

Yu-Hsin Lin

Okay. So I can take that. So right now, we are focused on the FDA with the PDUFA date in February 12. So that's our top priority, we'll be highly focused in the next 6 months on getting the drug approved. So the European filing will probably be sometime after the FDA approval, we want to align everything with the FDA, the approval and all that, and there will be the consistent message and communications with the regulatory authorities outside of the U.S. given what we discussed with the FDA and the approval and then there will be our strategy for ongoing regulatory filings.

Operator

And your next question comes from Tazeen Ahmad with Bank of America.

Tazeen Ahmad

In terms of manufacturing, have you stated where your manufacturing site is and whether or not that facility has completed an FDA inspection recently? Or is that going to be part of the requirement to get approval? And then secondly, I just wanted to get your latest thoughts on the possibility of an AdCom just given the consolidated time that the FDA would have to review, when do you think is the latest realistically that you would be told if the agency decided to hold on.

Yu-Hsin Lin

There's a few questions there. So I'll answer the first one, and I probably have to get you to repeat the last 2, 3 questions. So the first one, we do have a CDMO in the U.S. These are all the -- we're not at the privileged to review right now the names of the CDMOs, but these are all big names in the field -- in the industry. So we have ex U.S. and then a U.S.-based CDMO for that. So I hope that answers your question.

What's the second and third question?

Tazeen Ahmad

It was more about the FDA. And given a consolidated time line for review, what is your thought about having an AdCom as the agency talked about that. And realistically, when is the latest they could tell you if they were going to give you an AdCom?

Yu-Hsin Lin

So right now, we don't believe there has AdCom been planned, but that doesn't mean that further down the line, the FDA would want to use AdCom, so nothing on that right now. So I would say that once we have more updates further down the line, then we'll probably review that -- update that at a more appropriate time. But at this stage, we just received the acceptance, so we don't have any further details on that.

Operator

And your next question comes from the line of Steve Seedhouse with Cantor.

Steven Seedhouse

Great. Thanks so much. Congrats on the NDA filing acceptance in the U.S. I was hoping you could just confirm or clarify that you expect a priority review voucher if you receive approval and if so, if you'd look to auction that just for the purposes of us modeling cash runway?

Yu-Hsin Lin

Hao, do you want to have the cash runway, so you want to answer this?

Hao-Yuan Chuang

Well, yes, we do expect that if we receive approval, we should get the priority review voucher just because we do have the rare pediatric disease designation. We have not decided whether we're going to sell it or we're going to use it. So we will confirm that later, but we continue to monitor the market and our own pipeline, et cetera.

Steven Seedhouse

Okay. And then I also was hoping you could just provide an update on the geographic atrophy trial, whether you're still planning an interim readout later this year and what the precise timing of an update from that interim analysis might be?

Yu-Hsin Lin

Sure, I can answer this question. But isn't that the question regarding the cash runway?

Steven Seedhouse

I was just interested in the voucher pediatric voucher for our own modeling purposes, but how do you want to answer it?

Yu-Hsin Lin

All right. So the GA interim analysis fall during the busiest time with interacting with the FDA. So with the PDUFA date in mid-February, I would expect the busiest time to be in December and January 2027. So with that time line, our top priority is with the FDA approval. So I suspect that with the interim analysis for the GA will probably be sometime first quarter next year, probably after February.

Operator

Your next question comes from the line of Graig Suvannavejh with Mizuho. [Operator Instructions].

And we'll move on to the next question for now. Next question comes from Yi Chen with H.C. Wainwright.

Yi Chen

Just to clarify, has the FDA clearly indicated that the label will include patients over the age of 20 years old. Is that correct?

Yu-Hsin Lin

So right now, there haven't been any discussion on the label yet. I believe there will come sometime data in the process, in the review process. But at this stage, given the data and all that, we expect that we would be able to get the full label or the more broader label. I'll ask Hendrik to give more expert advice on this. Hendrik?

Hendrik Scholl

Yes, I'm happy to. And I think it's important to understand that lesion growth is not dramatically different across different age groups. That was shown in the ProgStar study, we have essentially the same progression rate of patients any age under the 18, and 18 to 50, and patients 50 plus, so slightly larger but still a similar progression rate when we look at DDAF progression. Given that the underlying cause of the disease, namely ABCA4 dysfunction is exactly the same. I would see no reason why the label would not include patients older than 20. But I think it's important that we do not really want to comment on potential label while the NDA is under review.

Yi Chen

Got it. Do you currently have data regarding how many more percentage of patients are compliant with the dosing regimen after 24 months?

Yu-Hsin Lin

Sure. Nathan, do you want to answer this question?

Nathan L. Mata

I'm sorry, could you repeat the question? Sorry, I think my volume...

Yi Chen

What percentage of patients are -- have been compliant with the dosing regimen after 24 months?

Nathan L. Mata

In the GA study?

Yu-Hsin Lin

In the Stargardt side.

Nathan L. Mata

In excess of 90%.

Yi Chen

Okay. And my last question is what's your estimate time line for submission in Japan?

Yu-Hsin Lin

Japan concurrently is happening at the same time. So given the Sakigake designation, it will probably be around 3 months after FDA approval, they want to approve the drug in Japan. So it's happening as we speak with the FDA submission and the PMDA submission is in parallel.

Yi Chen

Got it. Thank you very much.

Operator

[Operator Instructions]. And I see no further questions at this time. This concludes today's call. Thank you for attending. You may now disconnect.